News | January 28, 2022
Lupin signs promotional agreement with Exeltis on SOLOSEC
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Go-ahead for pivotal clinical trial which is expected to commence by March
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Subscribe To Our Newsletter & Stay Updated
